COPENHAGEN, Denmark, June 7, 2011 /PRNewswire-Asia/ -- Nearly one in five people with diabetes are regularly unable to attend a full day at work due to disruption caused by episodes of dangerously low blood sugar, known as a hypoglycaemic event.A new survey, focusing on productivity loss following hypoglycaemic events, was published today in the journal Value in Health. The survey was conducted with 1,404 people with type 1 and type 2 diabetes who had reported a hypoglycaemic event in the preceding month, in the US, UK, Germany and France.
(Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO )
Key conclusions from the survey were:
"Many people with diabetes struggle with hypoglycaemia on a regular basis," said lead researcher and health psychologist Dr. Meryl Brod. "This not only has an impact on their working lives, but increases the need to self-monitor blood glucose levels. Additionally, the events occurring during sleep are a challenge for people with diabetes."
The survey also revealed that patients conducted 5.6 extra blood glucose tests to measure their blood sugar in the next seven days after the event and 24.9% contacted a healthcare professional (either primary care physician, hospital, diabetes clinic, or other healthcare worker) as a result of the event. Among patients using insulin, 25% reported decreasing their insulin dose following the event.
Maintaining strict glycaemic control has long-term advantages for people with diabetes in reducing complications. Symptoms of a hypoglycaemic event, when the blood sugar becomes too low, often include pounding heart, trembling, hunger, sweating, difficulty concentrating or confusion. People with diabetes, treated with insulin, can experience 1-3 events per month.
The complete study can be found in the July issue of Value in Health and also online at: http://www.valueinhealthjournal.com/. The study was sponsored by Novo Nordisk.
Further information on diabetes:
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.
[*This is an aggregate number and does not account for differences in reimbursement that may exist in each country.]
© 2011 Novo Nordisk 144108 June 2011